CDXS
Price
$2.72
Change
+$0.05 (+1.87%)
Updated
Aug 28 closing price
Capitalization
245.53M
62 days until earnings call
CRSP
Price
$53.05
Change
-$0.48 (-0.90%)
Updated
Aug 28 closing price
Capitalization
4.82B
61 days until earnings call
Interact to see
Advertisement

CDXS vs CRSP

Header iconCDXS vs CRSP Comparison
Open Charts CDXS vs CRSPBanner chart's image
Codexis
Price$2.72
Change+$0.05 (+1.87%)
Volume$678.89K
Capitalization245.53M
CRISPR Therapeutics AG
Price$53.05
Change-$0.48 (-0.90%)
Volume$1.45M
Capitalization4.82B
CDXS vs CRSP Comparison Chart in %
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. CRSP commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Buy and CRSP is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (CDXS: $2.72 vs. CRSP: $53.05)
Brand notoriety: CDXS and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 61% vs. CRSP: 45%
Market capitalization -- CDXS: $245.53M vs. CRSP: $4.82B
CDXS [@Biotechnology] is valued at $245.53M. CRSP’s [@Biotechnology] market capitalization is $4.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, both CDXS and CRSP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 3 TA indicator(s) are bullish while CRSP’s TA Score has 2 bullish TA indicator(s).

  • CDXS’s TA Score: 3 bullish, 5 bearish.
  • CRSP’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than CRSP.

Price Growth

CDXS (@Biotechnology) experienced а -3.55% price change this week, while CRSP (@Biotechnology) price change was +0.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

CDXS is expected to report earnings on Oct 30, 2025.

CRSP is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.83B) has a higher market cap than CDXS($246M). CRSP YTD gains are higher at: 34.782 vs. CDXS (-42.977). CDXS has higher annual earnings (EBITDA): -52.78M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. CDXS (66.3M). CDXS has less debt than CRSP: CDXS (69M) vs CRSP (215M). CDXS has higher revenues than CRSP: CDXS (57.2M) vs CRSP (35M).
CDXSCRSPCDXS / CRSP
Capitalization246M4.83B5%
EBITDA-52.78M-533.5M10%
Gain YTD-42.97734.782-124%
P/E RatioN/AN/A-
Revenue57.2M35M163%
Total Cash66.3M1.72B4%
Total Debt69M215M32%
FUNDAMENTALS RATINGS
CDXS vs CRSP: Fundamental Ratings
CDXS
CRSP
OUTLOOK RATING
1..100
7364
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6248
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (42) in the Chemicals Specialty industry is in the same range as CRSP (64) in the Biotechnology industry. This means that CDXS’s stock grew similarly to CRSP’s over the last 12 months.

CDXS's Profit vs Risk Rating (100) in the Chemicals Specialty industry is in the same range as CRSP (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to CRSP’s over the last 12 months.

CDXS's SMR Rating (100) in the Chemicals Specialty industry is in the same range as CRSP (100) in the Biotechnology industry. This means that CDXS’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Price Growth Rating (48) in the Biotechnology industry is in the same range as CDXS (62) in the Chemicals Specialty industry. This means that CRSP’s stock grew similarly to CDXS’s over the last 12 months.

CRSP's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that CRSP’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSCRSP
RSI
ODDS (%)
Bearish Trend 5 days ago
82%
Bearish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 15 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SOLCF0.05N/A
+0.13%
SOL Global Investments Corp.
HSHZY9.15N/A
N/A
Hoshizaki Corporation
NTTDF24.00N/A
N/A
NTT DATA GROUP CORPORATION
CEGHF0.41N/A
N/A
CHINA ED GROUP HLDGS LTD.
TLGYF13.09-0.31
-2.31%
TLGY Acquisition Corporation

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+1.87%
DNLI - CDXS
51%
Loosely correlated
+0.32%
BEAM - CDXS
51%
Loosely correlated
-0.06%
PRAX - CDXS
49%
Loosely correlated
-1.98%
NTLA - CDXS
47%
Loosely correlated
+1.58%
CRSP - CDXS
47%
Loosely correlated
-0.90%
More

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-0.90%
RXRX - CRSP
69%
Closely correlated
-0.51%
BEAM - CRSP
67%
Closely correlated
-0.06%
NTLA - CRSP
63%
Loosely correlated
+1.58%
CRBU - CRSP
60%
Loosely correlated
-2.02%
PRME - CRSP
58%
Loosely correlated
+0.29%
More